The Week In... Medical Devices (15-19/07)
  • Posted on: 19/07/2019
  • Category: Industry

The Week In... Medical Devices (15-19/07)

Got five minutes? The MHRA launches a consultation on how best to engage with patients and the public, the world’s first full colour 3D printing technology is used in kidney cancer surgery, and the MD of Roche Diabetes Care says it’s time for the industry to work with health systems to speed up innovation access.

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Head of Business Development, Ryan Wooller, at, or get in touch on 07748 464 079.

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to, or give our offices a ring!

UL to close UK medical device notified body operation

UL International will stop operating as a U.K. medical device notified body and severely limit its in vitro diagnostic activities from September onward. 

MHRA launches consultation on how to best engage patients and the public

The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15/07/2019), launched a 12-week consultation on how to best engage and involve patients in the Agency’s work.

3D printing technology could improve hospital patient care

The world’s only full colour, multi-material 3D printing technology is being used within France’s Bordeaux University Hospital (CHU) to improve kidney cancer surgery.

Carers urged to engage with chief regulator over safety of medical devices

The chief regulator for medical devices and equipment wants to engage with end-users and their carers to ensure concerns over safety issues are heard more clearly. 

A true partnership

Michael Goetzl says it’s time for industry to work in true partnership with health systems “at every step of the way” to speed up access to innovation. 

BSI 'overwhelmed' with work ahead of EU MDR, but bullish on market, exec says

The countdown to May 26, 2020, is on. That's when device makers have to comply with the European Medical Device Regulation, designed to ramp up stringency and breadth of pre- and post-market review infrastructure.

While you’re here…

…and are interested in our content, why not sign up to our newsletter? It’s just below here.